Moderna tries its hand at CRISPR through a new development pact with Metagenomi
Moderna has always been thinking about how mRNA could transform the gene editing space, according to Eric Huang. In fact, they looked at it about a decade ago — but at the time, they were still a small, preclinical biotech, and technology like that would take some time to mature.
Then the pandemic hit, and the rest is history.
“Now, I think it’s the right time,” said Huang, CSO of Moderna’s genomics business.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,300+ biopharma pros reading Endpoints daily — and it's free.